Zander Therapeutics, Inc
Healthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | |
|---|---|---|
| Revenue | — | — |
| Operating income | −$1.8M | −$2.2M |
| Net income | $308,516 | −$2.2M |
| Total assets | $2.7M | $472,202 |
| Total liabilities | $1.9M | $1.1M |
| Equity | $768,062 | −$627,359 |
| EPS (diluted) | — | — |
| Shares out. | 6.6M | 4.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- —
- Net margin
- —
- Return on equity
- 40.2%
- Return on assets
- 11.6%
- Return on capital (ROCE)
- −233.6%
- Liabilities / assets
- 71.2%
- Debt / equity
- 2.47×
- Book value / share
- $0.12
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -11.31distress
- Accruals / assets
- 56.6%high accruals
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Q/Amissed a reporting deadline ↗May 24, 2019
- NT 10-Qmissed a reporting deadline ↗May 14, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Director / officer changeJan 22, 2020
- Other material eventJan 7, 2020
- Entered a material agreementSep 18, 2019
- Other material eventJul 2, 2019
- Changed auditorJun 18, 2019
- Prior financials not reliable (restatement)May 31, 2019
- Entered a material agreementApr 26, 2019
- Entered a material agreementApr 19, 2019
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KJan 22, 2020
- 8-KFORM 8-KJan 7, 2020
- 8-KFORM 8-KDec 18, 2019
- 10-QFORM 10-QOct 25, 2019
- 8-KFORM 8-KSep 18, 2019
- 10-KFORM 10-KAug 30, 2019
- 8-KFORM 8-KJul 2, 2019
- UPLOADJul 2, 2019
- 10-Q/AFORM 10-Q/AJun 28, 2019
- 10-Q/AFORM 10-Q/AJun 28, 2019
- 8-KFORM 8-KJun 18, 2019
- CORRESPJun 12, 2019
- UPLOADJun 11, 2019
- CORRESPJun 10, 2019
- UPLOADJun 5, 2019
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.